Coxsackievirus Infections

A heterogeneous group of infections produced by coxsackieviruses, including HERPANGINA, aseptic meningitis (MENINGITIS, ASEPTIC), a common-cold-like syndrome, a non-paralytic poliomyelitis-like syndrome, epidemic pleurodynia (PLEURODYNIA, EPIDEMIC) and a serious MYOCARDITIS.

Also Known As:

Networked: 69 relevant articles (0 outcomes, 4 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Myocarditis (Carditis)
2.	Infection
3.	Inflammation
4.	Alcoholic Pancreatitis
5.	Retroviridae Infections (Infection, Retrovirus)

Experts

1.	Luo, Honglin: 3 articles (01/2011 - 08/2003)
2.	Zhang, Jingchun: 3 articles (01/2011 - 08/2003)
3.	Lowenstein, Charles J: 3 articles (03/2007 - 08/2004)
4.	Gao, Guang: 2 articles (01/2011 - 01/2008)
5.	Wong, Jerry: 2 articles (01/2011 - 01/2008)
6.	Flodström-Tullberg, Malin: 2 articles (05/2010 - 02/2005)
7.	Fang, Dianne: 2 articles (01/2009 - 05/2008)
8.	Horwitz, Marc S: 2 articles (01/2009 - 05/2008)
9.	Straka, Nadine: 2 articles (01/2009 - 05/2008)
10.	Shanina, Iryna: 2 articles (01/2009 - 05/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Coxsackievirus Infections:

1.	UbiquitinIBA 09/01/2014 - "Taken together, the findings in this study suggest a novel mechanism through which coxsackievirus infection induces increased accumulation of ubiquitin conjugates and subsequent viral damage. " 09/01/2014 - "Coxsackievirus infection induces an abnormal accumulation of ubiquitin aggregates that are generally believed to be noxious to the cells and have a key role in viral pathogenesis. " 01/01/2008 - "Coxsackievirus infection promotes protein ubiquitination, contributing to effective viral replication, probably through ubiquitin modification of viral polymerase." 08/01/2003 - "We have previously shown that coxsackievirus infection facilitates the ubiquitin/proteasome processing of the cell-cycle protein cyclin D1 and the tumor suppressor p53, which raises the possibility that the ubiquitin/proteasome pathway may be used by virus to promote viral replication. "
2.	Proteasome Endopeptidase Complex (Proteasome)IBA 01/03/2011 - "The present study explores the role of tripeptidyl peptidase II (TPPII), a serine peptidase contributing to protein turnover by acting downstream of the proteasome, in regulating coxsackievirus infection. " 08/01/2003 - "We have previously shown that coxsackievirus infection facilitates the ubiquitin/proteasome processing of the cell-cycle protein cyclin D1 and the tumor suppressor p53, which raises the possibility that the ubiquitin/proteasome pathway may be used by virus to promote viral replication. "
3.	adenovirus receptorIBA 08/29/2014 - "This study demonstrates that hiPSC-CMs express the coxsackievirus and adenovirus receptor, are susceptible to coxsackievirus infection, and can be used to predict antiviral drug efficacy. " 04/30/2004 - "Alternatively spliced soluble coxsackie-adenovirus receptors inhibit coxsackievirus infection."
4.	Serine (L-Serine)FDA Link 01/03/2011 - "The present study explores the role of tripeptidyl peptidase II (TPPII), a serine peptidase contributing to protein turnover by acting downstream of the proteasome, in regulating coxsackievirus infection. "
5.	SeleniumIBA 06/01/2000 - "In studies of coxsackievirus infection and selenium deficiency in mice, we found that mice fed a selenium-deficient diet developed myocarditis, but mice fed a diet adequate in selenium did not. "
6.	tripeptidyl-peptidase 2IBA 01/03/2011 - "The present study explores the role of tripeptidyl peptidase II (TPPII), a serine peptidase contributing to protein turnover by acting downstream of the proteasome, in regulating coxsackievirus infection. "
7.	Immunoglobulin M (IgM)IBA 05/01/1985 - "Comparison of serodiagnosis of group B coxsackievirus infections by an immunoglobulin M capture enzyme immunoassay versus microneutralization." 02/01/1975 - "Fresh Coxsackie virus infections were observed in 16 sera, more than 50% of these sera showed an abnormally high level of IgM." 09/01/1973 - "On retrospective review of the clinical diagnosis, some of the patients in the control group with IgM antibody were found to have had additional clinical findings which could be attributed to a coxsackievirus infection. " 12/01/1989 - "Anti-mouse IgM immunoglobulin protects weanling mice from Coxsackievirus infection." 01/01/1987 - "Criteria of actual coxsackie virus infection have been defined, including a significant rise of titer of virus neutralizing antibodies and/or presence of virus-specific IgM antibodies. "
8.	AntigensIBA 10/01/2009 - "Our findings have implications for the efficiency of antigen cross-presentation during coxsackievirus infection." 07/01/1998 - "These results show that diabetes induced by Coxsackie virus infection is a direct result of local infection leading to inflammation, tissue damage, and the release of sequestered islet antigen resulting in the re-stimulation of resting autoreactive T cells, further indicating that the islet antigen sensitization is an indirect consequence of the viral infection." 01/01/1990 - "Newborns with suppurative-inflammatory disease were found to be at high risk of intrauterine infection with Coxsackie enteroviruses from mothers with persistent enterovirus infection; in 54.9%, congenital Coxsackie virus infection was confirmed by virus antigen identification in the urine sediment cells and autopsy material. " 04/01/1953 - "[Preparation of purified antigen (protamine-ether) for serologic diagnosis of Coxsackie virus infections]." 07/01/2004 - "Identification of autoantibodies with the corresponding antigen for repetitive coxsackievirus infection-induced cardiomyopathy."
9.	AntibodiesIBA 02/01/1975 - "150 sera from newborn infants were examined by means of counter current electrophoresis for precipitating antibodies against Coxsackie virus Group B and Group A, Type 9 to detect pre- or perinatal Coxsackie virus infections. " 01/01/1968 - "Characterization of antibodies produced in natural and experimental coxsackievirus infections." 01/01/1987 - "In sera of patients with actual coxsackie virus infection, a higher proportion of infection with some types of coxsackie viruses, along with the presence of antibodies against a larger number of coxsackie virus types has been found, as compared to sera from patients without actual coxsackie virus infection, and/or, in sera of healthy blood donors (control group). " 01/01/1987 - "Criteria of actual coxsackie virus infection have been defined, including a significant rise of titer of virus neutralizing antibodies and/or presence of virus-specific IgM antibodies. " 01/01/1979 - "No viruses could be isolated from stools; the titres of anti-Coxsackie viruses B1 to 6 complement fixing antibodies and anti-Coxsackie virus B4 neutralizing antibodies, compared to controls, indicated that Coxsackie virus infection was not associated with the onset of diabetes in these children. "
10.	Complement System Proteins (Complement)IBA 01/01/1959 - "[Value of the complement fixation reaction in the diagnosis of Coxsackie virus infections]." 01/01/1979 - "No viruses could be isolated from stools; the titres of anti-Coxsackie viruses B1 to 6 complement fixing antibodies and anti-Coxsackie virus B4 neutralizing antibodies, compared to controls, indicated that Coxsackie virus infection was not associated with the onset of diabetes in these children. " 12/01/2012 - "We describe two previously healthy children who were hospitalized in the same period in different departments of our University with clinical signs of Kawasaki syndrome, which were treated with intravenous immunoglobulins and acetylsalicylic acid: in both cases, Coxsackie virus infection was concurrently demonstrated by enzyme-linked immunosorbent assay, and complement fixation test identified antibodies to serotype B3. "

Therapies and Procedures

1.	Therapeutics 01/01/2011 - "This review addresses antiviral therapeutics for cardiac coxsackievirus infections discovered over the last 25 years. " 01/01/2011 - "Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections." 12/07/2004 - "Interferons (IFNs)-alpha and -beta perform a fundamental role in innate and adaptive antiviral responses, thereby presenting as candidate therapeutics for coxsackievirus infections. "
2.	Transplantation (Transplant Recipients) 01/01/2006 - "No evidence suggests relapse of Coxsackie virus infection 5 months after transplantation. "
3.	Lasers (Laser) 12/01/1995 - "We measured unloaded sarcomere shortening velocity (V0) with laser diffraction (HeNe, lambda = 623.8 nm) 7 days after coxsackievirus infection (M) (n = 7) and after infection + monoclonal antibodies to eliminate T cells (T) (n = 4) and in normals (N) (n = 8). "